Jessica Fye's questions to Beigene Ltd (ONC) leadership • Q4 2024
Question
Jessica Fye from JPMorgan Chase & Co. asked about BeiGene's expectations for the upcoming pirtobrutinib (Pirto) readouts in frontline CLL and what would constitute appropriate cross-trial comparisons against BRUKINSA.
Answer
Global Head of R&D Lai Wang downplayed the significance of the Pirto trials, noting one is against an outdated standard of care (chemo) and the other is in a mixed population with a non-practice-changing endpoint. She positioned BeiGene's own BTK degrader as a superior asset, highlighting the planned head-to-head trial against Pirto in a later-line setting.